Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CLL immunotoxins.

Arthur E Frankel, Robert J Kreitman

    Leukemia Research
    |July 26, 2005
    PubMed
    Summary
    This summary is machine-generated.

    New immunotoxins targeting interleukin-4 receptors (IL4R) show promise for treating chronic lymphocytic leukemia (CLL) that has relapsed or is refractory to chemotherapy. A fraction of patients exhibited extreme sensitivity to this novel agent.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    DNA methylation-based classification of hematolymphoid neoplasms.

    Blood advances·2026
    Same author

    Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

    Blood·2026
    Same author

    Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

    Science translational medicine·2026
    Same author

    Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

    Leukemia & lymphoma·2025
    Same author

    Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.

    Blood·2025
    Same author

    Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy.

    JCO precision oncology·2025
    Same journal

    A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.

    Leukemia research·2026
    Same journal

    FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study.

    Leukemia research·2026
    Same journal

    CD244 modulates bone marrow infiltrating CD8<sup>+</sup> T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.

    Leukemia research·2026
    Same journal

    Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

    Leukemia research·2026
    Same journal

    Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

    Leukemia research·2026
    Same journal

    CRS and ICANS as class-level adverse event for CD20 ×CD3 bispecific T-cell engagers: A Bayesian analysis of a nationwide database.

    Leukemia research·2026
    See all related articles

    Area of Science:

    • Oncology
    • Immunology
    • Molecular Biology

    Background:

    • Immunotoxins, combining cell-specific ligands with peptide toxins, are investigated for treating relapsed/refractory malignancies, including chronic lymphocytic leukemia (CLL).
    • Previous CLL immunotoxins (e.g., T101-ricin A, DAB(486)IL2) have shown some efficacy with limited myelosuppression, but new therapeutic agents are still required.

    Discussion:

    • Kay and colleagues developed a novel immunotoxin targeting the interleukin-4 receptor (IL4R) on CLL B cells using a recombinant IL4-pseudomonas exotoxin fusion protein (IL-4(38--37)-PE38KDEL).
    • This approach leverages the IL4R as a target on malignant B cells in CLL.
    • The study highlights the potential of targeted protein therapy in hematologic malignancies.

    Key Insights:

    • A subset of patients (19%) demonstrated extreme sensitivity of their CLL cells to the novel IL-4 receptor-targeted immunotoxin.

    Related Experiment Videos

  • This targeted approach resulted in significant tumor cell killing in sensitive individuals.

    • Outlook:

    • The recombinant IL4-pseudomonas exotoxin fusion protein (IL-4(38--37)-PE38KDEL) represents a promising new therapeutic candidate for CLL treatment.
    • Further clinical evaluation is warranted to confirm its efficacy and safety profile in a broader patient population.